Emerging 5-HT receptor antagonists for the treatment of Schizophrenia

References

• Global Burden of Disease Study Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Aug 22;386(9995):743–800.
   PubMed Web of Science ®Google Scholar
• Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull. 2018 Oct 17;44(6):1195–1203.
   PubMed Web of Science ®Google Scholar
• National Institute of Mental Health. Schizophrenia. Bethesda, MD: National Institute of Mental Health; 2009.
   Google Scholar
• Nuechterlein KH, Barch DM, Gold JM, et al. Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004 Dec 15;72(1):29–39.
   PubMed Web of Science ®Google Scholar
• Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull. 2004;30(2):279–293.
   PubMed Web of Science ®Google Scholar
• Rice DP, Miller LS The economic burden of schizophrenia: conceptual and methodological issues, and cost estimates. Handbook of mental health economics and health policy, Vol. 1: schizophrenia. Handbook of mental health economics and health policy. Oxford, England: John Wiley & Sons; 1996. p. 321–334.
   Google Scholar
• Helfer B, Samara MT, Huhn M, et al. Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry. 2016 Sep 1;173(9):876–886.
   PubMed Web of Science ®Google Scholar
• Kraepelin E. Dementia Praecox and Paraphrenia. Edinburgh: Livingstone; 1919.
   Google Scholar
• Cutting J. First rank symptoms of schizophrenia: their nature and origin. Hist Psychiatry. 2015 Jun;26(2):131–146.
   PubMed Web of Science ®Google Scholar
• Rabinowitz J, Berardo CG, Bugarski-Kirola D, et al. Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis. Schizophr Res. 2013 Nov;150(2–3):339–342.
   PubMed Web of Science ®Google Scholar
• Bobes J, Arango C, Garcia-Garcia M, et al. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry. 2010 Mar;71(3):280–286.
   PubMed Web of Science ®Google Scholar
• Millan MJ, Fone K, Steckler T, et al. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol. 2014 May;24(5):645–692.
   PubMed Web of Science ®Google Scholar
• Strauss GP, Sandt AR, Catalano LT, et al. Negative symptoms and depression predict lower psychological well-being in individuals with schizophrenia. Compr Psychiatry. 2012 Nov;53(8):1137–1144.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick B, Fenton WS, Carpenter WT Jr., et al. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006 Apr;32(2):214–219.
   PubMed Web of Science ®Google Scholar
• Mitra S, Mahintamani T, Kavoor AR, et al. Negative symptoms in schizophrenia. Ind Psychiatry J. 2016 Jul-Dec;25(2):135–144.
   PubMedGoogle Scholar
• Kraepelin E. Dementia praecox and paraphrenia. Hungtington, NY: Robert E. Krieger Publishing Co. Inc.; 1971.
   Google Scholar
• Bleuler E. Dementia praecox or the group of schizophrenias. New York, NY: International Universities Press; 1950.
   Google Scholar
• Green MF, Harvey PD. Cognition in schizophrenia: past, present, and future. Schizophr Res Cogn. 2014 Mar;1(1):e1–e9.
   PubMedGoogle Scholar
• Bowie CR, Reichenberg A, Patterson TL, et al. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry. 2006 Mar;163(3):418–425.
   PubMed Web of Science ®Google Scholar
• Bowie CR, Leung WW, Reichenberg A, et al. Predicting schizophrenia patients’ real-world behavior with specific neuropsychological and functional capacity measures. Biol Psychiatry. 2008 Mar 1;63(5):505–511.
   PubMed Web of Science ®Google Scholar
• Strassnig MT, Raykov T, O’Gorman C, et al. Determinants of different aspects of everyday outcome in schizophrenia: the roles of negative symptoms, cognition, and functional capacity. Schizophr Res. 2015 Jun;165(1):76–82.
   PubMed Web of Science ®Google Scholar
• Nucifora FC Jr., Mihaljevic M, Lee BJ, et al. Clozapine as a model for antipsychotic development. Neurotherapeutics. 2017 Jul;14(3):750–761.
   PubMed Web of Science ®Google Scholar
• Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry. 2006 Oct;63(10):1079–1087.
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010 Jan;36(1):71–93.
   PubMed Web of Science ®Google Scholar
• Rabinowitz J, Werbeloff N, Caers I, et al. Negative symptoms in schizophrenia–the remarkable impact of inclusion definitions in clinical trials and their consequences. Schizophr Res. 2013 Nov;150(2–3):334–338.
   PubMed Web of Science ®Google Scholar
• Amador XF, Kirkpatrick B, Buchanan RW, et al. Stability of the diagnosis of deficit syndrome in schizophrenia. Am J Psychiatry. 1999 Apr;156(4):637–639.
   PubMed Web of Science ®Google Scholar
• Palmer BW, Heaton RK, Paulsen JS, et al. Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology. 1997 Jul;11(3):437–446.
   PubMed Web of Science ®Google Scholar
• Wilk CM, Gold JM, McMahon RP, et al. No, it is not possible to be schizophrenic yet neuropsychologically normal. Neuropsychology. 2005 Nov;19(6):778–786.
   PubMed Web of Science ®Google Scholar
• Strassnig MT, Bowie CR, Pinkham AE, et al. Which levels of cognitive impairments and negative symptoms are related to functional deficits in schizophrenia? J Psychiatr Res. 2018;104:124–129.
   PubMed Web of Science ®Google Scholar
• Elkis H, Buckley PF. Treatment-resistant schizophrenia. Psychiatr Clin North Am. 2016 Jun;39(2):239–265.
   PubMed Web of Science ®Google Scholar
• Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry. 1994 Sep;55(Suppl):B:82–7.
   Google Scholar
• Green MF, Marshall BD Jr., Wirshing WC, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry. 1997 Jun;154(6):799–804.
   PubMed Web of Science ®Google Scholar
• Keefe RS, Seidman LJ, Christensen BK, et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry. 2004 Jun;161(6):985–995.
   PubMed Web of Science ®Google Scholar
• Woodward ND, Purdon SE, Meltzer HY, et al. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res. 2007 Jan;89(1–3):211–224.
   PubMed Web of Science ®Google Scholar
• Crespo-Facorro B, Rodriguez-Sanchez JM, Perez-Iglesias R, et al. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. J Clin Psychiatry. 2009 Apr 21;70(5):717–729.
   PubMed Web of Science ®Google Scholar
• Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 2001 Feb;158(2):176–184.
   PubMed Web of Science ®Google Scholar
• Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007 Jun;64(6):633–647.
   PubMed Web of Science ®Google Scholar
• Loebel AD, Siu CO, Cucchiaro JB, et al. Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia. CNS Spectr. 2014 Apr;19(2):197–205.
   PubMed Web of Science ®Google Scholar
• Andreasen NC. The scale for the assessment of negative symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry Suppl. 1989 Nov;(7):49–58. DOI:10.1192/S0007125000291496
   PubMedGoogle Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276.
   PubMed Web of Science ®Google Scholar
• Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994 Jun;151(6):825–835.
   PubMed Web of Science ®Google Scholar
• White L, Harvey PD, Opler L, et al. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and negative syndrome scale. The PANSS Study Group. Psychopathology. 1997;30(5):263–274.
   PubMed Web of Science ®Google Scholar
• Khan A, Liharska L, Harvey PD, et al. Negative symptom dimensions of the positive and negative syndrome scale across geographical regions: implications for social, linguistic, and cultural consistency. Innov Clin Neurosci. 2017 Dec 1;14(11–12):30–40.
   PubMedGoogle Scholar
• Harvey PD, Khan A, Keefe R. Using the Positive and Negative Syndrome Scale (PANSS) to define different domains of negative symptoms: prediction of everyday functioning by impairments in emotional expression and emotional experience. Innov Clin Neurosci. 2017;14:18–22.
   PubMedGoogle Scholar
• Strauss GP, Horan WP, Kirkpatrick B, et al. Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. J Psychiatr Res. 2013 Jun;47(6):783–790.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick B, Strauss GP, Nguyen L, et al. The brief negative symptom scale: psychometric properties. Schizophr Bull. 2011 Mar;37(2):300–305.
   PubMed Web of Science ®Google Scholar
• Raskin A, Pelchat R, Sood R, et al. Negative symptom assessment of chronic schizophrenia patients. Schizophr Bull. 1993;19(3):627–635.
   PubMed Web of Science ®Google Scholar
• Horan WP, Kring AM, Gur RE, et al. Development and psychometric validation of the clinical assessment interview for negative symptoms (CAINS). Schizophr Res. 2011 Nov;132(2–3):140–145.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick B, Saoud JB, Strauss GP, et al. The brief negative symptom scale (BNSS): sensitivity to treatment effects. Schizophr Res. 2018 Jul;197:269–273.
   PubMed Web of Science ®Google Scholar
• Strauss GP, Zamani Esfahlani F, Sayama H, et al. Network analysis indicates that avolition is the most central domain for the successful treatment of negative symptoms: evidence from the roluperidone randomized clinical trial. Schizophr Bull. 2020 Jan 28.
   Web of Science ®Google Scholar
• Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998 Dec 1;9(17):3897–3902.
   PubMed Web of Science ®Google Scholar
• Kometer M, Schmidt A, Jäncke L, et al. Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. J Neurosci. 2013 Jun 19;33(25):10544–10551.
   PubMed Web of Science ®Google Scholar
• Sommer IEC, Kleijer H, Visser L, et al. Successful treatment of intractable visual hallucinations with 5-HT ((2A)) antagonist ketanserin. BMJ Case Rep. 2018 Jun 27;2018. DOI:10.1136/bcr-2018-224340
   PubMedGoogle Scholar
• Monti JM. Serotonin 5-HT(2A) receptor antagonists in the treatment of insomnia: present status and future prospects. Drugs Today (Barc). 2010 Mar;46(3):183–193.
   PubMed Web of Science ®Google Scholar
• Forecasts for HMR’s M100907 antipsychotic putney [Internet]. London: The Pharma Letter; 1998 [cited 2020 Mar 20]. Available from: https://www.thepharmaletter.com/article/forecasts-for-hmr-s-m100907-antipsychotic
   Google Scholar
• Zheng W, Cai DB, Zhang QE, et al. Adjunctive ondansetron for schizophrenia: A systematic review and meta-analysis of randomized controlled trials. J Psychiatr Res. 2019 Jun;113:27–33.
   PubMed Web of Science ®Google Scholar
• Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014 Feb 8;383(9916):533–540.
   PubMed Web of Science ®Google Scholar
• ACADIA pharmaceuticals presents positive top-line results from pivotal phase 3 harmony trial of pimavanserin in patients with dementia-related psychosis at 12th clinical trials on Alzheimer’s disease (CTAD) meeting [Internet]. San Diego, CA: Business Wire; December 4, 2019 [cited 2020 Mar 20]. Available from: https://www.businesswire.com/news/home/20191204005956/en/
   Google Scholar
• Meltzer HY, Elkis H, Vanover K, et al. Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. Schizophr Res. 2012 Nov;141(2–3):144–152.
   PubMed Web of Science ®Google Scholar
• ACADIA pharmaceuticals announces top-line results from phase 3 enhance trial of pimavanserin as adjunctive treatment for patients with schizophrenia [Internet]. San Diego, CA: Business Wire; July 22, 2019 [cited 2020 Mar 20]. Available from: https://www.businesswire.com/news/home/20190722005666/en/.
   Google Scholar
• ACADIA pharmaceuticals announces positive top-line results from advance trial of pimavanserin as treatment for negative symptoms of schizophrenia [Internet]. San Diego, CA: Business Wire; November 25, 2019 [cited 2020 Mar 20]. Available from: https://www.businesswire.com/news/home/20191125005784/en/ *Trial of pimavanserin as adjunctive treatment in patients with predominantly negative symptoms showing promise for the treatment of negative symptoms.
   Google Scholar
• Meltzer HY, Massey BW, Horiguchi M. Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. Curr Pharm Biotechnol. 2012 Jun;13(8):1572–1586.
   PubMed Web of Science ®Google Scholar
• Moore TJ, Cohen MR, Fuberg CD, et al. Safety signals for two novel drugs [Internet]. QuarterWatch. 2017 [cited 2020 Mar 20] Available from: https://ismp.org/sites/default/files/attachments/2018-01/2017Q1_0.pdf
   Google Scholar
• Moreno GM, Gandhi R, Lessig SL, et al. Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine. Neurology. 2018 Oct 23;91(17):797–799.
   PubMed Web of Science ®Google Scholar
• Davidson M, Saoud J, Staner C, et al. Efficacy and safety of MIN-101: A 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia. Am J Psychiatry. 2017 Dec 1;174(12):1195–1202.
   PubMed Web of Science ®Google Scholar
• Katz JL, Su TP, Hiranita T, et al. A role for sigma receptors in stimulant self administration and addiction. Pharmaceuticals (Basel). 2011;4(6):880–914.
   PubMedGoogle Scholar
• Lever JR, Miller DK, Green CL, et al. A selective sigma-2 receptor ligand antagonizes cocaine-induced hyperlocomotion in mice. Synapse. 2014 Feb;68(2):73–84.
   PubMed Web of Science ®Google Scholar
• Skuza G. Pharmacology of sigma (σ) receptor ligands from a behavioral perspective. Curr Pharm Des. 2012;18(7):863–874.
   PubMed Web of Science ®Google Scholar
• Vilner BJ, Bowen WD. Modulation of cellular calcium by sigma-2 receptors: release from intracellular stores in human SK-N-SH neuroblastoma cells. J Pharmacol Exp Ther. 2000 Mar;292(3):900–911.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Su TP. The potential role of sigma-1 receptors in lipid transport and lipid raft reconstitution in the brain: implication for drug abuse. Life Sci. 2005 Aug 19;77(14):1612–1624.
   PubMed Web of Science ®Google Scholar
• Gewirtz GR, Gorman JM, Volavka J, et al. BMY 14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology. 1994 Feb;10(1):37–40.
   PubMed Web of Science ®Google Scholar
• Horiguchi M, Huang M, Meltzer HY. The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exp Ther. 2011 Aug;338(2):605–614.
   PubMed Web of Science ®Google Scholar
• Keefe RSE, Harvey PD, Khan A, et al. Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms: results From a Randomized Controlled Trial. J Clin Psychiatry. 2018 May/Jun;79(3). DOI: 10.4088/JCP.17m11753
   PubMed Web of Science ®Google Scholar
• Harvey PD, Saoud JB, Luthringer R, et al. Effects of Roluperidone (MIN-101) on two dimensions of the negative symptoms factor score: reduced emotional experience and reduced emotional expression. Schizophr Res. 2020 Jan;215:352–356.
   PubMed Web of Science ®Google Scholar
• Friedman JI, Adler DN, Temporini HD, et al. Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacology. 2001 Sep;25(3):402–409.
   PubMed Web of Science ®Google Scholar
• McClure MM, Barch DM, Romero MJ, et al. The effects of guanfacine on context processing abnormalities in schizotypal personality disorder. Biol Psychiatry. 2007 May 15;61(10):1157–1160.
   PubMed Web of Science ®Google Scholar
• McClure MM, Graff F, Triebwasser J, et al. Guanfacine augmentation of a combined intervention of computerized cognitive remediation therapy and social skills training for schizotypal personality disorder. Am J Psychiatry. 2019 Apr 1;176(4):307–314.
   PubMed Web of Science ®Google Scholar
• Snyder GL, Vanover KE, Zhu H, et al. Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. Psychopharmacology (Berl). 2015 Feb;232(3):605–621.
   PubMed Web of Science ®Google Scholar
• FDA approves Intra-Cellular Therapies’ novel antipsychotic CAPLYTA [Internet]. December 23, 2019 [cited 2020 May 1]. Available from: https://ir.intracellulartherapies.com/news-releases/news-release-details/fda-approves-intra-cellular-therapies-novel-antipsychotic
   Google Scholar
• Intra-Cellular Therapies I. Caplyta (lumateperone) capsules, for oral use: US prescribing information. 2019.
   Google Scholar
• Lieberman JA, Davis RE, Correll CU, et al. ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial. Biol Psychiatry. 2016 Jun 15;79(12):952–961.
   PubMed Web of Science ®Google Scholar
• Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003 Jul;60(7):681–690.
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013 Sep 14;382(9896):951–962.
   PubMed Web of Science ®Google Scholar
• Correll CU, Davis RE, Weingart M, et al. Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2020 Jan 8; DOI:10.1001/jamapsychiatry.2019.4379
   Web of Science ®Google Scholar
• Charron A, Hage CE, Servonnet A, et al. 5-HT2 receptors modulate the expression of antipsychotic-induced dopamine supersensitivity. Eur Neuropsychopharmacol. 2015 Dec;25(12):2381–2393.
   PubMed Web of Science ®Google Scholar
• Salokangas RK, McGlashan TH. Early detection and intervention of psychosis: a review. Nord J Psychiatr. 2008;62(2):92–105.
   PubMed Web of Science ®Google Scholar
• Harvey PD, McClure MM, Patterson TL, et al. Impairment in functional capacity as an endophenotype candidate in severe mental illness. Schizophr Bull. 2012 Nov;38(6):1318–1326.
   PubMed Web of Science ®Google Scholar
• McClure MM, Harvey PD, Bowie CR, et al. Functional outcomes, functional capacity, and cognitive impairment in schizotypal personality disorder. Schizophr Res. 2013 Mar;144(1–3):146–150.
   PubMed Web of Science ®Google Scholar
• Tsuang MT, Van Os J, Tandon R, et al. Attenuated psychosis syndrome in DSM-5. Schizophr Res. 2013 Oct;150(1):31–35.
   PubMed Web of Science ®Google Scholar
• Harvey PD, Jones MT. Functional deficits in attenuated psychosis syndrome and related conditions: current and future treatment options. Schizophr Res Cogn. 2019 Sep;17:100152.
   PubMedGoogle Scholar
• McClure MM, Harvey PD, Goodman M, et al. Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum. Neuropsychopharmacology. 2010 May;35(6):1356–1362.
   PubMed Web of Science ®Google Scholar
• Rosell DR, Zaluda LC, McClure MM, et al. Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder. Neuropsychopharmacology. 2015 Jan;40(2):446–453.
   PubMed Web of Science ®Google Scholar